Based on the evidence available, how should we be integrating and incorporating ctDNA profiling — liquid biopsies — with tissue-based whole exome NGS, including longitudinal biopsies?

Based on the evidence available, how should we be integrating and incorporating ctDNA profiling — liquid biopsies — with tissue-based whole exome NGS, including longitudinal biopsies?

Based on the evidence available, how should we be integrating and incorporating ctDNA profiling — liquid biopsies — with tissue-based whole exome NGS, including longitudinal biopsies?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Prof. Jean-Yves Blay, MD, PhD

Prof. Jean-Yves Blay, MD, PhD

Professor of Medicine
Université Claude Bernard
Lyon, France
Scientific Director
Canceropole Lyon Rhône Alpes